Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03228667
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
- NCT03228667 ↗
- Active, not recruiting
- ImmunityBio, Inc.
- Focused
We haven't built an HCP commentary report on NCT03228667 (N-803 + pembrolizumab, N-803 + nivolumab and 10 more in Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03228667 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
- Interventions
- N-803 + Pembrolizumab; N-803 + Nivolumab; N-803 + Atezolizumab; N-803 + Avelumab; N-803 + Durvalumab; N-803 + Pembrolizumab + PD-L1 t-haNK; N-803 + Nivolumab + PD-L1 t-haNK; N-803 + Atezolizumab + PD-L1 t-haNK; N-803 + Avelumab + PD-L1 t-haNK; N-803 + Durvalumab + PD-L1 t-haNK; N-803 + Docetaxel + Pembrolizumab; N-803 + Docetaxel + Nivolumab
- Arms
- Cohort 1 · Other
- Cohort 2 · Other
- Cohort 3 · Other
- Cohort 4 · Experimental
- Cohort 5 · Experimental
- Cohort 6 · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.
- Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 11, 2018
- Primary completion
- Aug 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT03228667 · updated Jan 14, 2026